Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis Pharma Plans Brand Acquisitions In India Expansion Move

This article was originally published in PharmAsia News

Executive Summary

India's Aventis Pharma plans to acquire branded drugs and expand as part of an effort to be major hub for parent Sanofi-Aventis' research and development and manufacturing. Managing Director Shallesh Ayyangar said he could not say how much the Paris-based company would invest in the India expansion. Sanofi already has two large plants in India, one for active pharmaceutical ingredients. Ayyangar said his unit plans to launch extensions or upgrades of existing drugs and drugs aimed at diabetes, oncology and the central nervous system. Sanofi also is looking at conducting more clinical trials in India. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts